Exploring how a new receptor affects CAR-T cell effectiveness in treating lymphoma
Official title: Investigating a Novel Inhibitory Receptor in Regulating CAR-T Cell Persistence and Function
Funded at Cleveland Clinic Lerner Com-Cwru · NIH-10947466 · Data updated 2026-11-12
This study is looking at a special receptor that might make CAR-T cell therapy for lymphoma less effective, and it aims to see if blocking this receptor can help these immune cells work better in both mice and people.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cleveland Clinic Lerner Com-Cwru NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project start | July 8, 2024 |
| Project end | June 30, 2026 |
| Funding year | 2024 |
| Award (this year) | $413,971 |
| NIH project number | 1R21CA286304-01A1 |
| Project ID | NIH-10947466 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with lymphoma who are considering or have undergone CAR-T cell therapy.
✕Less likely to help
Patients with other types of cancer or those who are not eligible for CAR-T cell therapy may not benefit from this research.
What this research studies
This research investigates the role of a specific inhibitory receptor that may limit the effectiveness and longevity of CAR-T cells, a type of immunotherapy used to treat lymphoma. The study will first assess how this receptor impacts the performance of CAR-T cells in mouse models. Following this, the research will analyze the presence of this receptor in human CAR-T cells and evaluate whether blocking it can enhance their function. The findings aim to improve CAR-T cell therapies, potentially leading to better outcomes for patients with lymphoma.
Why it matters
Potential benefit: If successful, this research could lead to more effective CAR-T cell therapies, reducing relapse rates in lymphoma patients.
How similar studies have gone: Previous research has shown promise in enhancing CAR-T cell therapies by targeting inhibitory receptors, indicating a potential for success in this approach.
Where this research is happening
-
Cleveland Clinic Lerner Com-Cwru
Cleveland, United States Active
Researchers
- Principal investigator: Wang, Li Lily — Cleveland Clinic Lerner Com-Cwru
- Study coordinator: Wang, Li Lily
Related research
Other NIH-funded projects on the same topics.
-
Susceptibility-based MRI biomarkers for multiple sclerosis
A short-term study aims to test MRI biomarkers that could help diagnose and predict MS in patients, using advanced imaging techniques.
-
Population genomics in peripartum cardiomyopathy
A gene-focused study to understand why some women develop heart failure around and after pregnancy, with an emphasis on African ancestry.
-
Broad antiviral therapy by targeting a key enzyme in nucleotide synthesis
A plan to block a human enzyme that many viruses need, with the aim of creating a broad-spectrum antiviral treatment for infections like SARS-CoV-2, influenza, and HSV-1.
-
Cellular-level Vascular Oculomics for Monitoring Systemic Vascular Health
A multi-site project using eye imaging and AI to monitor blood vessel health in people, with devices and software developed across four clinical sites.
-
Cellular-level Eye Signals to Track Vascular Health
A multi-site project aims to create and test portable imaging devices and AI tools that can monitor blood vessel health through the eye.
-
Outcomes in cirrhosis from different causes and the role of HIV and simvastatin
This study looks at how cirrhosis from alcohol, HIV, and other causes affects patients and whether simvastatin can influence outcomes.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.